Diabetes, Obesidad y otros Factores de Riesgo Vascular. Enfermedades Autoinmunes Sistémicas

Lineas de Investigación

01. Autoimmune diseases

02. Vascular Risk Factors

03. Thromboembolic Disease

04. Geriatrics and Palliative Care



Proyectos de Investigación

IDeIBIMA_001_2018 Impacto de la modificación del estilo de vida sobre la función muscular y cognitiva de una población obesa metabólicamente sana de edad avanzada.

FUNDACION PÚBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
AYUDAS PARA LA FINANCIACIÓN DE PROYECTOS I+De+IBIMA 2018

PI18/00766 Población obesa metabólicamente sana de edad avanzada: Estudio –ómico (Epigenética, metabolómica, metagenómica) y su relación con contaminantes ambientales

INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - PROYECTOS DE INVESTIGACIÓN EN SALUD 2018

MS15/00028 Contrato Miguel Servet Tipo I María Rosa Bernal López

INSTITUTO DE SALUD CARLOS III
CONTRATOS MIGUEL SERVET TIPO I 2015

PI17/00855 PREDIMED+DM:Efecto de una pérdida de peso con la dieta mediterránea hipocalórica y promoción de la actividad física en la prevención de la diabetes tipo 2 en personas con síndrome metabólico

INSTITUTO DE SALUD CARLOS III
ACCIÓN ESTRATÉGICA EN SALUD - PROYECTOS DE INVESTIGACIÓN EN SALUD (FIS) 2017

CP15/00028 Proyecto de Investigación Miguel Servet Tipo I María Rosa Bernal López: Involvement of epigenetic mechanisms and the gut microbiota in the development of insulin resistance in a pediatric metabolically healthy obese population

INSTITUTO DE SALUD CARLOS III
CONTRATOS MIGUEL SERVET TIPO I 2015

PC-0198-2017 Efecto de la Intervención en el Estilo de Vida en el Desarrollo de Nefropatía Diabética en Pacientes Con Prediabetes Sin Evidencia de Lesión Micro/macrovascular

CONSEJERÍA DE SALUD
PROYECTOS DE INVESTIGACIÓN COORDINADOS 2017

Estudios Clínicos

GLARGL07710. Estudio Fase IV para evaluar la eficacia y seguridad de la nueva insulina Glargina 300 u/ml (GLA-300) durante la hospitalización y la intensificación al alta en pacientes con diabetes tipo 2.

SANOFI-AVENTIS, S.A.
Fase: IV ENSAYO CLINICO COMERCIAL

GLP116174. Estudio a largo plazo, aleatorizado, doble ciego, controlado con placebo para determinar el efecto de Albiglutida, cuando se añade al tratamiento hipoglucemiante estándar, sobre eventos cardiovasculares mayores en pacientes con Diabetes Mellitus Tipo2

GLAXOSMITHKLINE, S.A.
Fase: IV ENSAYO CLINICO COMERCIAL

e-PREDICE2013. Prevención temprana de complicaciones por diabetes en personas con hiperglucemia en Europa (e-PREDICE)

FUNDACIÓN DE INVESTIGACIÓN EN RED EN ENFERMEDADES CARDIOVASCULARES (FIRCAVA)
Fase: III ENSAYO CLINICO INDEPENDIENTE

Publicaciones científicas

  • Todo
  • D1
  • Q1
  • Q2
  • Otro
Trends in Diabetes-Related Potentially Preventable Hospitalizations in Adult Population in Spain, 1997⁻2015: A Nation-Wide Population-Based Study.

Gómez-Huelgas R, Lara-Rojas CM, López-Carmona MD, Jansen-Chaparro S, Barba R, Zapatero A, Guijarro-Merino R, Tinahones FJ, Pérez-Belmonte LM, Bernal-López MR.
J Clin Med. 2019 Apr 11;8(4).

We aimed to assess national trends in the rates of diabetes-related potentially preventable hospitalizations (overall and by preventable condition) in the total adult population of Spain. We performed a population-based study of all adult patients with diabetes who were hospitalized from 1997 to 2015. Overall potentially preventable hospitalizations and hospitalizations by diabetes-related preventable conditions (short-term complications, long-te […]

Effects of a long-term lifestyle intervention on metabolically healthy women with obesity: Metabolite profiles according to weight loss response.

Palau-Rodriguez M, Garcia-Aloy M, Miñarro A, Bernal-Lopez MR, Brunius C, Gómez-Huelgas R, Landberg R, Tinahones FJ, Andres-Lacueva C.
Clin Nutr. 2019 Feb 16.

The benefits of weight loss in subjects with metabolically healthy obesity (MHO) are still a matter of controversy. We aimed to identify metabolic fingerprints and their associated pathways that discriminate women with MHO with high or low weight loss response after a lifestyle intervention, based on a hypocaloric Mediterranean diet (MedDiet) and physical activity. […]

Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Authors’ reply.

Gómez-Huelgas R, Pérez-Belmonte LM, López-Sampalo A, Morilla-Herrera JC, Bellosta-Ymbert JM, Bernal-López MR.
Pol Arch Intern Med. 2019 Feb 28;129(2):143-144.

[…]


Rev Clin Esp. 2019 May;219(4):171-176.

To compare the structure, resources and activity of the internal medicine units (IMUs) of the Spanish National Health System (SNHS) in 2013 and 2016. To analyse the differences between IMUs in 2016 by hospital size. […]


Rev Clin Esp. 2019 Feb 19.

Climate change consists mainly of global warming, a result of the so-called greenhouse effect, which is caused by certain gases, including carbon dioxide (CO2), produced mainly through the combustion of fossil fuels, such as coal and oil. Global warming is a severe threat for future populations because it can cause a considerable rise in sea levels, a greater frequency and intensity of extreme meteorological phenomena and even the extinction of c […]


Rev Clin Esp. 2019 Mar;219(2):79-80.

[…]

Dietary inflammatory index and all-cause mortality in large cohorts: The SUN and PREDIMED studies.

Garcia-Arellano A, Martínez-González MA, Ramallal R, Salas-Salvadó J, Hébert JR, Corella D, Shivappa N, Forga L, Schröder H, Muñoz-Bravo C, Estruch R, Fiol M, Lapetra J, Serra-Majem L, Ros E, Rekondo J, Toledo E, Razquin C, Ruiz-Canela M; SUN and PREDIMED Study Investigators.
Clin Nutr. 2018 May 24.

Inflammation is known to be related to the leading causes of death including cardiovascular disease, several types of cancer, obesity, type 2 diabetes, depression-suicide and other chronic diseases. In the context of whole dietary patterns, the Dietary Inflammatory Index (DII®) was developed to appraise the inflammatory potential of the diet. […]

Management of elderly patients with type 2 diabetes in long-term care and skillednursing facilities.

Gómez-Huelgas R, Pérez-Belmonte LM, Rivera-Cabeo I, Morilla-Herrera JC, Bellosta-Ymbert JM, Bernal-López MR.
Pol Arch Intern Med. 2019 Feb 28;129(2):137-140.

[…]


Rev Clin Esp. 2019 May;219(4):208-217.

Sodium-glucose cotransporter-2 inhibitors have changed the concept of the effects that hypoglycemic drugs have on hearth failure (HF). For the first time, a therapeutic group has modified the evolution of HF. Its effect goes beyond glycemic control, and different theories have been postulated to justify this benefit. In the article we sent, we analyze the influence of the different pharmacological groups used in type 2 diabetes mellitus on HF, an […]


Rev Clin Esp. 2019 Apr;219(3):124-129.

Diabetes mellitus is associated with a marked increase in cardiovascular disease. In this study, we analysed the prevalence of diabetes mellitus in hospitalised patients in Spain in 2015 and the burden of associated cardiovascular disease. […]

Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.

Carretero Gómez J, Arévalo Lorido JC, Gómez Huelgas R, García de Lucas D, Mateos Polo L, Varela Aguilar JM, Seguí Ripoll JM, Ena J; Diabetes, Obesity, and Nutrition Spanish Working Group.
Can J Diabetes. 2019 Apr;43(3):186-192.

Scientific literature about the combination of glucagon-like peptide-1 receptor agonists (GLP-1ra) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in older patients is scarce. We sought to assess the real-world efficacy and safety of SGLT2 inhibitors and GLP-1ra combination therapy in older patients (>65 years of age). […]

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators.
Lancet. 2018 Oct 27;392(10157):1519-1529.

Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. […]

Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study).

Pérez-Belmonte LM, Gómez-Doblas JJ, Millán-Gómez M, López-Carmona MD, Guijarro-Merino R, Carrasco-Chinchilla F, de Teresa-Galván E, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R.
J Clin Med. 2018 Sep 11;7(9).

The use of noninsulin antihyperglycaemic drugs in the hospital setting has not yet been fully described. This observational study compared the efficacy and safety of the standard basal-bolus insulin regimen versus a dipeptidyl peptidase-4 inhibitor (linagliptin) plus basal insulin in medicine department inpatients in real-world clinical practice. We retrospectively enrolled non-critically ill patients with type 2 diabetes with mild to moderate hy […]

National trends in diabetes mellitus hospitalization in Spain 1997-2010: Analysis of over 5.4 millions of admissions.

Lara-Rojas CM, Pérez-Belmonte LM, López-Carmona MD, Guijarro-Merino R, Bernal-López MR, Gómez-Huelgas R.
Eur J Intern Med. 2019 Feb;60:83-89.

To analyze national trends in the rates of hospitalizations (all-cause and by principal discharge diagnosis) in total diabetic population of Spain. […]


Rev Clin Esp. 2019 Jan – Feb;219(1):18-25.

Information for the adequate management of diabetic patients at hospital discharge is limited. We aimed to evaluate the impact of implementation of recommendations of the Spanish consensus for the management hospital discharge in patients with type 2 diabetes or hyperglycaemia during hospitalization. […]

Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts.

Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Fitó M, Gea A, Hernán MA, Martínez-González MA; PREDIMED Study Investigators.
N Engl J Med. 2018 Jun 21;378(25):e34.

Observational cohort studies and a secondary prevention trial have shown inverse associations between adherence to the Mediterranean diet and cardiovascular risk. […]

Impact in Plasma Metabolome as Effect of Lifestyle Intervention for Weight-Loss Reveals Metabolic Benefits in Metabolically Healthy Obese Women.

Almanza-Aguilera E, Brunius C, Bernal-Lopez MR, Garcia-Aloy M, Madrid-Gambin F, Tinahones FJ, Gómez-Huelgas R, Landberg R, Andres-Lacueva C.
J Proteome Res. 2018 Aug 3;17(8):2600-2610.

Little is known regarding metabolic benefits of weight loss (WL) on the metabolically healthy obese (MHO) patients. We aimed to examine the impact of a lifestyle weight loss (LWL) treatment on the plasma metabolomic profile in MHO individuals. Plasma samples from 57 MHO women allocated to an intensive LWL treatment group (TG, hypocaloric Mediterranean diet and regular physical activity, n = 30) or to a control group (CG, general recommendations o […]

To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with metformin and/or gliclazide. […]


Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263